ReviewCancers2020
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Gut microbiota and intestinal polyps: a systematic review and meta-analysis based on 16S rRNA gene sequencing.Gut pathogens · 2025Review
- Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer.Journal of translational medicine · 2024Article
- Article
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- Molecular methods for colorectal cancer screening: Progress with next-generation sequencing evolution.World journal of gastrointestinal oncology · 2023Review
- Lactobacillus rhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant.Journal of translational medicine · 2023Article
- Colorectal Cancer Immunotherapy: State of the Art and Future Directions.Gastro hep advances · 2023Article
- Investigation of Microbial Translocation,Cancers · 2022Article
- Review
- Review
- Factors that influence the pancreatic and duodenal microbiome in patients undergoing pancreatic surgery.PloS one · 2022Article
- Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?Frontiers in oncology · 2022Review
- Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives.Journal of clinical and translational research · 2021Review
- Review
- The Role of Gut Microbiota in Tumor Immunotherapy.Journal of immunology research · 2021Review
- Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy.Journal of microscopy and ultrastructureReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last few years, immunotherapy has been considered as a key player in the treatment of solid tumors. Immune checkpoint inhibitors (ICIs) have become the breakthrough treatment, with prolonged responses and improved survival results. ICIs use the immune system to defeat cancer by breaking the axes that allow tumors to escape immune surveillance. Innate and adaptive immunity are involved in mechanisms against tumor growth. The gut microbiome and its role in such mechanisms is a relatively new study field. The presence of a high microbial variation in the gut seems to be remarkably important for the efficacy of immunotherapy, interfering with innate immunity. Metabolic and immunity pathways are related with specific gut microbiota composition. Various studies have explored the composition of gut microbiota in correlation with the effectiveness of immunotherapy. Colorectal cancer (CRC) patients have gained little benefit from immunotherapy until now. Only mismatch repair-deficient/microsatellite-unstable tumors seem to respond positively to immunotherapy. However, gut microbiota could be the key to expanding the use of immunotherapy to a greater range of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.